The studies described below were carried out using the scientific method of casuistry (also called longitudinal case study). In this, persons with particular illnesses are monitored before treatment and for as long as possible thereafter.
The scientific gold standard of medical research, the randomised placebo-controlled double blind study, in which ill and healthy people are given either the real treatment or a placebo treatment at random, and neither the patient nor the researchers know who is in which group, is seen as unethical in the field of cancer treatment because placebo treatments (i.e., non-treatment) may be fatal for those affected.
The results obtained by casuistry cannot exclude placebo effects per se, but relative conclusions, e.g., that one method is better than another can be drawn by comparing longitudinal studies of various treatment methods for a particular illness.
The following significant studies on ECT are presented below:
- Statistics from our institute (continue reading)
- Large study by Prof. Dr. Yuling Xin from China with over 9,000 treated patients (Overview and further graphics)
- Study by Profs. Tschissow/Sokolow in P.A. Gerzen (continue reading)
- Mini-study by Prof. Grönemeyer (continue reading)
- Study of prostate cancer by Prof. Vogel, University of Frankfurt (continue reading)
- Study from Russia (continue reading)
- Further studies of middle and late stage lung tumours (see below)
ECT with middle to late stage tumours in the lungs. Even in these stages, 25.6% total remission und 46.4% partial remission was achieved. This refers to mono-therapies.